Table 5 Performance of different standard and POC assays at PSA cut-off 4 ng/ml (CI confidence interval, PC prostate cancer, PSA prostate specific antigen, a from chi-square test)
From: Assessment of a new point-of-care system for detection of prostate specific antigen
PSA Immulite® | PSA Centaur® | Concile® | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
No PC | PC | No PC | PC | No PC | PC | ||||||
PSA < 4 | 20 | 5 | 25 (36.8 %) | PSA < 4 | 25 | 7 | 32 (47.1 %) | PSA < 4 | 22 | 5 | 27 (39.7 %) |
PSA ≥ 4 | 13 | 30 | 43 (63.2 %) | PSA ≥ 4 | 8 | 28 | 36 (52.9 %) | PSA ≥ 4 | 11 | 30 | 41 (60.3 %) |
33 (48.50 %) | 35 (51.50 %) | 68 | 33 (48.50 %) | 35 (51.50 %) | 68 | 33 (48.50 %) | 35 (51.50 %) | 68 | |||
Significance levela | P = 0.0002 | P < 0.0001 | P < 0.0001 | ||||||||
95 % CI | 95 % CI | 95 % CI | |||||||||
Sensitivity | 85.71 % | 69.74 to 95.19 % | 80.00 % | 63.06 to 91.56 % | 85.71 % | 69.74 to 95.19 % | |||||
Specificity | 60.61 % | 42.14 to 77.09 % | 75.76 % | 57.74 to 88.91 % | 66.67 % | 48.17 to 82.04 % | |||||
Positive predictive value | 69.77 % | 53.87 to 82.82 % | 77.78 % | 60.85 to 89.88 % | 73.17 % | 57.06 to 85.78 % | |||||
Negative predictive value | 80.00 % | 59.30 to 93.17 % | 78.12 % | 60.03 to 90.72 % | 81.48 % | 61.92 to 93.70 % |